Celldex Therapeutics, Inc.  

(Public, NASDAQ:CLDX)   Watch this stock  
Find more results for celldex
-0.39 (-1.31%)
After Hours: 29.36 -0.03 (-0.10%)
Mar 6, 5:12PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 29.07 - 30.07
52 week 10.76 - 31.04
Open 29.54
Vol / Avg. 2.00M/2.32M
Mkt cap 2.92B
P/E     -
Div/yield     -
EPS -1.32
Shares 97.93M
Beta 2.74
Inst. own 85%
Apr 29, 2015
Q1 2015 Celldex Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 4, 2015
Celldex Therapeutics Inc at Cowen Health Care Conference
Feb 24, 2015
Q4 2014 Celldex Therapeutics Inc Earnings Release
Feb 24, 2015
Q4 2014 Celldex Therapeutics Inc Earnings Call
Feb 12, 2015
Celldex Therapeutics Inc at Leerink Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -2154.50% -3292.80%
Operating margin -2170.01% -3414.11%
EBITD margin - -3319.27%
Return on average assets -49.12% -39.68%
Return on average equity -56.60% -44.44%
Employees 161 -
CDP Score - -


53 Frontage Rd Ste 220
HAMPTON, NJ 08827-4034
United States - Map
+1-908-2007500 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's drug candidates include CDX-110, CDX-011 and CDX-1127. CDX-110, is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). CDX-1127 is a human monoclonal antibody that targets CD27. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology programs, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system.

Officers and directors

Larry Ellberger Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Anthony S. Marucci President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Avery W. Catlin CPA Chief Financial Officer, Senior Vice President, Secretary
Age: 66
Bio & Compensation  - Reuters
Tibor Keler Ph.D. Executive Vice President, Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
Thomas Andrew Davis M.D. Executive Vice President, Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Ronald A. Pepin Ph.D. Senior Vice President, Chief Business Officer
Age: 58
Bio & Compensation  - Reuters
Richard A. Van Den Broek Director
Age: 48
Bio & Compensation  - Reuters
Herbert J. Conrad Independent Director
Age: 81
Bio & Compensation  - Reuters
George O. Elston CPA Independent Director
Age: 50
Bio & Compensation  - Reuters
Harry H. Penner Jr., J.D. Independent Director
Age: 68
Bio & Compensation  - Reuters